Research graph
References from Short-term ketamine interventions for depressive disorders: practical best-practice recommendations for psychiatrists using oral, subcutaneous, and nasal formulations. Local targets link to admitted publications; unresolved targets remain external evidence.
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
10.1192/bjo.2021.1061 · 2022 · External reference
Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation
10.1176/appi.ajp.2020.20081251 · 2021 · External reference
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance
10.1080/15622975.2020.1836399 · 2021 · External reference
Guidelines for ketamine use in clinical psychiatry practice
10.1192/bjo.2024.62 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial
10.1001/jamapsychiatry.2025.1317 · 2025 · External reference
Oral ketamine for depression, 1: pharmacologic considerations and clinical evidence
10.4088/jcp.19f12820 · 2019 · External reference
Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial
10.1001/jamapsychiatry.2019.1189 · 2019 · External reference
Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression
10.1176/appi.ajp.2019.19020172 · 2019 · External reference
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
10.1192/bjp.2023.79 · 2023 · External reference
Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study
10.1192/bjp.2018.196 · 2019 · External reference
Oral ketamine for depression: an updated systematic review
10.1080/15622975.2023.2169349 · 2023 · External reference
Oral ketamine for depression: a systematic review
10.4088/jcp.18r12475 · 2019 · External reference
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
10.1038/s41591-024-03063-x · 2024 · External reference
Oral prolonged-release ketamine for treatment-resistant depression: two randomized clinical trials
10.1001/jamanetworkopen.2026.19121 · 2026 · External reference
Intranasal ketamine for depression in adults: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials
10.3389/fpsyg.2021.648691 · 2021 · External reference
The efficacy and safety of intranasal formulations of ketamine and esketamine for the treatment of major depressive disorder: a systematic review
10.3390/pharmaceutics15122773 · 2023 · External reference
A consensus statement on the use of ketamine in the treatment of mood disorders
10.1001/jamapsychiatry.2017.0080 · 2017 · External reference
Safety and tolerability of the acute ketamine treatment in treatment-resistant depression: focus on comorbidities interplay with dissociation and psychomimetic symptoms
10.3390/ph16020173 · 2023 · External reference
Ketamine for major depressive disorder during an inpatient psychiatric admission: effectiveness, adverse events, and lessons learned
10.1016/j.jad.2024.01.207 · 2024 · External reference
Combination of ketamine and electroconvulsive therapy in treatment resistant depression
10.1016/j.jad.2025.04.017 · 2025 · External reference
Non-parenteral ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing
10.1007/s40263-022-00897-2 · 2022 · External reference
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
10.1038/s41380-024-02478-9 · 2024 · External reference
Subcutaneous ketamine in depression: a systematic review
10.3389/fpsyt.2021.513068 · 2021 · External reference
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study
10.1016/j.euroneuro.2023.04.011 · 2023 · External reference
Side-effects associated with ketamine use in depression: a systematic review
10.1016/s2215-0366(17)30272-9 · 2018 · External reference
Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depressive disorder for use by adult specialist mental health services in New Zealand
10.1192/bjo.2023.577 · 2023 · External reference
Psychiatric and legal considerations for ketamine treatment within prison settings
10.3389/fpsyt.2024.1316108 · 2024 · External reference
